NasdaqGS:NTRABiotechs
Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)
Natera recently received a favorable ruling from the U.S. District Court in Delaware, which upheld the validity of its three asserted MRD patents and granted a 30% ongoing royalty on certain post-injunction revenues from infringing MRD-related product sales by ArcherDx and Invitae.
This court decision reinforces Natera’s intellectual property strength in molecular residual disease testing, potentially improving the company’s competitive position and revenue visibility in this specialized...